Evaluation of Safety of Low Level Laser Device Treatment in Chronic Wounds

Diabetic Foot Ulcer Clinical Trial

Official title:

Evaluation of Safety of Low Level Laser MC-8XL Device Treatment in Chronic Wounds

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03204149
• Other study ID #: BBL-0043-16
• Status: Terminated
• Phase: N/A
• Start date: June 14, 2017
• Est. completion date: June 14, 2019

Study information

• Verified date: September 2020
• Source: Medical Coherence LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double blind, placebo-controlled study to evaluate the safety of the low level laser MC-8XL device treatment in subjects with an unsuccessfully treated Diabetic Foot Ulcer (DFU) that has been present for at least 3 months.

Eligible subjects will be randomized to either Treatment group or Control group, following which, treatment of each subject will be provided by a qualified nurse at the clinic or in the home setting, everyday for up to 16 weeks.

Study assessments and adverse events monitoring will be also performed throughout the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: June 14, 2019
• Est. primary completion date: June 14, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Provide signed and dated Informed Consent Form

• Willing to comply with all study procedures and be available for the duration of the study

• Male or female, aged 18 to 90

• Having a DFU of at least 3 months duration that had not improved after prior standard wound treatments

• HbA1c of <11.0

• Size of wounds: 1-10 cm2

• Having DFU of grades 2 or 3 according to Wagner's classification

Exclusion Criteria:

• Immeasurable wounds or wounds that are unsuited to this laser treatment (usually due to the wound's location, e.g. in the area between the toes).

• Uncontrolled Diabetes defined as an HbA1c of > 11.0

• Arterial insufficiency, Doppler vascular assessment (if needed- Ankle Brachial Index (ABI) < 0.6)

• Osteomyelitis in the bone.

• Photosensitivity

• Pregnancy

• Presence of any suspicious pre-cancerous or cancerous lesions, or having cancer.

• Being on medications that are immunosuppressive, may affect peripheral blood flow or may affect normal wound healing.

• Being on medications that might cause photosensitivity.

• Participation in any other clinical trial testing a device or drug.

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcer
• Foot Ulcer

Intervention

Device:
• MC-8XL low level laser device and Standard wound care
The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group. Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed. After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded.
• Sham laser device and Standard wound care
The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group. Along with the sham device, the same generally accepted standard wound care procedures will be used.

Locations

Country	Name	City	State
Israel	Northern District Trauma & Wound Clinics Division, Maccabi Health Care Services	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Medical Coherence LLC

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	assessing device related and general adverse events	On a weekly basis until the end of the 16 week treatment period
Secondary	Wound Healing	Percent of wounds achieving complete wound closure, wound granulation and percent change in ulcer size/area	On a weekly basis until the end of the 16 week treatment period or until complete wound closure